Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
AAVACC has secured positive safety data for its lead candidate – a vaccine against the porcine epidemic diarrhea virus (PEDV).
Merck Animal Health has launched its PRIME PAC PRRS RR vaccine with the intention to tackle porcine reproductive and respiratory syndrome (PRRS) virus.
Belgian start-up ViroVet has received a grant from Flanders Innovation & Entrepreneurship (VLAIO) to spur development of its vaccine technology.
A team from the UK's Pirbright Institute are filing a patent for a newly-developed peste de petit ruminants (PPR) vaccine, which they used as part of a program in India.
GALVmed will receive $10 million in UK government aid to advance vaccine projects in Africa.
The UK's Pirbright Institute has received funding from the Bill & Melinda Gates Foundation to further the development of a low-cost foot-and-mouth disease (FMD) vaccine.
Zoetis has launched Core EQ Innovator, which it claims is the first and only equine vaccine to contain all five core equine disease antigens.
This year saw the 10th annual Kansas City Animal Health Investment Forum host a wide array of companies yearning to innovate and disrupt the animal health market. Animal Pharm analyst Daniel Willis gives an overview of the start-ups on display.
Pharmaq has signed strategic collaboration agreement with Vinh Hoan to work on advancing aquaculture health in Vietnam.
Laboratorios Hipra has gained approval from the European Medicines Agency for its Ubac inactivated vaccine for cattle.
Covenant Animal Health Partners has been launched to focus on bringing animal health innovations to market.
Scientists at the UK's Pirbright Institute are looking to better understand African swine fever (ASF) to aid the potential future development of a vaccine.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.